Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Sprint Bioscience AB is a biotechnology company engaged in the development of novel drug candidates targeting cancer and other life-threatening diseases. Headquartered in Sweden, the company's primary focus is on the early stages of drug development, leveraging its expertise in fragment-based drug discovery. Sprint Bioscience AB operates primarily within the healthcare sector, contributing significantly to oncology research by utilizing cutting-edge technology to improve treatment options. The company’s approach involves the rapid development and optimization of small molecules that can be further advanced through partnerships with larger pharmaceutical firms for clinical studies. This strategic collaboration model positions Sprint Bioscience AB as a key player in the drug discovery pipeline, facilitating the translation of innovative scientific research into therapeutic solutions. Sprint Bioscience AB is significant in the market for its ability to address the high demand for new cancer treatments, offering high-value partnerships and licensing opportunities. Its work not only impacts the pharmaceutical industry but also plays a crucial role in enhancing the long-term prospects for patients facing severe health challenges, underscoring its importance in the global effort to combat complex diseases.
kr 0.38
+kr 0.03 (+8.76%)
EOD Jun 26, 2026 · Twelve Data
Margins and capital returns are both well above average: 58.35% operating margin, ROIC at 151.88%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 154.7% YoY with margins expanding 87.9pp.
Even for strong businesses, today's 0x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
0.5x earnings, 0.6x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 153M
▲ +154.7% YoY
Net Income (TTM)
kr 84M
▲ +601.9% YoY
Op. Margin
57.49%
▲ +87.9pp YoY
ROIC
151.88%
▲ +234.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 70M
▲ +438.4% YoY
Op. Cash Flow (TTM)
kr 76M
▲ +481.3% YoY
Net Debt
-kr 127M
Net Cash Position
Cash & Equiv.
kr 127M
3Y CAGR: +68.2%
Continue Research
At a P/E of 0.5 and a price-to-free-cash-flow of 0.6, Sprint Bioscience AB (SPRINT.XSTO) trades below a two-stage DCF intrinsic value of about SEK 34.89 per share, so at SEK 0.38 the stock looks undervalued (8,961.8% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Sprint Bioscience AB scores 90/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 34.89 per share for SPRINT.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 26.17. At today's SEK 0.38, that puts the stock about 8,961.8% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Sprint Bioscience AB scores 90 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 57.5% operating margin and a 151.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. SPRINT.XSTO currently trades below its estimated intrinsic value and scores 90/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.